Repeated Radiofrequency Ablation Combined With Ablated Lesion Elimination and Transarterial Chemoembolization Improves the Outcome of Solitary Huge Hepatocellular Carcinomas 10 cm or Larger
Authors:
- Shan KeSKShan Ke
- Jun GaoJGJun Gao
- Jian KongJKJian Kong
- Xue-Mei DingXDXue-Mei Ding
- Hai-Gang NiuHNHai-Gang Niu
- Zong-Hai XinZXZong-Hai Xin
- Chun-Min NingCNChun-Min Ning
- Shi-Gang GuoSGShi-Gang Guo
- Xiao-Long LiXLXiao-Long Li
- Long ZhangLZLong Zhang
- Yong-Hong DongYDYong-Hong Dong
- Wen-Bing SunWSWen-Bing Sun
Open Access
- 1 April 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (16) , e3393
Abstract
This study investigated the effectiveness of a new strategy, repeated radiofrequency (RF) ablation combined with ablated lesion elimination following transarterial chemoembolization (TACE)/transarterial embolization (TAE), for solitary huge hepatocellular carcinoma (SHHCC) 10 cm or larger. From July 2008 to October 2015, 39 consecutive patients with SHHCC were screened. Of these, 12 were treated with TACE/TAE and repeated RF ablation (TACE/TAE + RF ablation group) and the remaining 27 patients were treated with the aforementioned new strategy (new strategy group). Local tumor progression (LTP)-free survival, intrahepatic distant recurrence (IDR)-free survival, and overall survival (OS) rates were obtained using the Kaplan-Meier method. Univariate and multivariate analyses were performed on several clinicopathological variables to identify factors affecting long-term outcome and intrahepatic recurrence. Correlation analysis was also performed. The 1-, 2-, and 3-year LTP-free survival rates and OS rates were significantly higher in the new strategy group than in the TACE/TAE + RF ablation group (82.9% vs 58.3%, 73.9% vs 29.2%, 18.5% vs 9.7%, P = 0.002; 92.0% vs 75.0%, 84.0% vs 33.3%, 32.7% vs 16.7%, P = 0.025). However, there was no significant difference between the 2 groups in the 1-, 2-, and 3-year IDR-free survival rates (P = 0.108). Using univariate analysis, alpha-fetoprotein (AFP > 200 ng/mL), ablative margin (AM > 1.0 cm), and well-differentiated cells were found to be significant factors for predicting LTP, IDR, and OS. Surgical elimination was found to be a significant factor only for predicting OS. In multivariate analyses, AFP (>200 ng/mL), AM (>1.0 cm), and well-differentiated cells were found to be significant independent factors linked to LTP, IDR, and OS. Correlation analysis indicated that AM > 1.0 cm was strongly associated with surgical elimination (P < 0.001, correlation coefficient = 0.877). For patients with SHHCC who were initially excluded from surgery, the new strategy including repeated RF ablation combined with ablated lesion elimination following TACE/TAE should now be considered as an alternative treatment.Keywords
This publication has 23 references indexed in Scilit:
- Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with CirrhosisRadiology, 2014
- Recent advances in radiofrequency ablation in the treatment of hepatocellular carcinoma and metastatic liver cancers.2009
- The Current Role of Radiofrequency Ablation in the Management of Hepatocellular CarcinomaAnnals of Surgery, 2009
- Solitary Large Hepatocellular CarcinomaAnnals of Surgery, 2009
- Sorafenib, a systemic therapy for hepatocellular carcinomaAnnals of Hepatology, 2008
- Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative MarginAmerican Journal of Roentgenology, 2007
- Percutaneous Local Ablative Therapy for Hepatocellular CarcinomaAnnals of Surgery, 2003
- Selection Criteria for Hepatic Resection in Patients with Large Hepatocellular Carcinoma Larger Than 10 Cm in Diameter1Journal of the American College of Surgeons, 2002
- Radiofrequency Ablation of the LiverAmerican Journal of Roentgenology, 2001
- Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrenceJournal of Surgical Oncology, 2000